SPDP
Based on 5 publication(s) in Google Scholar
SPDP (SPDP Crosslinker) is a short-chain crosslinker for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls. It is a glutathione cleavable ADC linker used for the antibody-drug conjugates (ADCs).
For research use only. We do not sell to patients.
- Purity: 99.14%
- CAS No.: 68181-17-9
- Formula: C12H12N2O4S2
- Molecular Weight:312.37
-
Storage:
-20°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) SPDP
More
Biological Activity
|
Disulfide Cleavable Linker |
Cleavable Linker |
Equal amounts of anti-CD11c and anti-CTLA-4 Abs (in borate buffered saline; pH 8.5) are activated using SPDP.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 68181-17-9
-
Appearance Solid
-
Molecular Weight 312.37
-
Formula C12H12N2O4S2
-
Color White to off-white
-
SMILES
O=C(ON1C(CCC1=O)=O)CCSSC2=NC=CC=C2
-
Synonyms
SPDP Crosslinker; Py-ds-Prp-OSu
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
ACS Appl Mater Interfaces
Aptamer-Modified Tetrahedral Framework Nucleic Acid Synergized with TGF-β3 to Promote Cartilage Protection in Osteoarthritis by Enhancing Chondrogenic Differentiation of MSCs. [Abstract]2024 Sep 25;16(38):50484-50496. PMID: 39282962 -
Bioeng Transl Med
Nanoalbumin-prodrug conjugates prepared via a thiolation-and-conjugation method improve cancer chemotherapy and immune checkpoint blockade therapy by promoting CD8+ T-cell infiltration. [Abstract]2022 Jul 30;8(1):e10377. PMID: 36684090 -
Colloids Surf B Biointerfaces
Improved targeting delivery of WED-load immunoliposomes modified with SP-A mAb for the treatment of pulmonary fibrosis. [Abstract]2023 Apr:224:113237. PMID: 36871414 -
Microb Cell Fact
Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression. [Abstract]2021 Mar 10;20(1):67. PMID: 33691697 -
ACS Omega
5'-NucA-SMCC-DM1 and 5'-NucA-SPDMV-DM1 are Potent Aptamer-Drug Conjugates against Pancreatic Cancer. [Abstract]2026 Feb 3;11(7):12461-12471. PMID: 41768714
Solvent & Solubility
DMSO : 250 mg/mL (800.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.66 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.66 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * The compound is unstable in solutions, freshly prepared is recommended.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lobedanz S et al. A periplasmic coiled-coil interface underlying TolC recruitment and the assembly of bacterial drug effluxpumps. Proc Natl Acad Sci U S A, 2007 Mar 13, 104(11):4612-7. [Content Brief]
[2]. Karumuthil-Melethil S et al. Dendritic cell-directed CTLA-4 engagement during pancreatic beta cell antigen presentation delays type 1diabetes. J Immunol 2010 Jun 15, 184(12):6695-708. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2013 mL | 16.0067 mL | 32.0133 mL | 80.0333 mL |
| 5 mM | 0.6403 mL | 3.2013 mL | 6.4027 mL | 16.0067 mL | |
| 10 mM | 0.3201 mL | 1.6007 mL | 3.2013 mL | 8.0033 mL | |
| 15 mM | 0.2134 mL | 1.0671 mL | 2.1342 mL | 5.3356 mL | |
| 20 mM | 0.1601 mL | 0.8003 mL | 1.6007 mL | 4.0017 mL | |
| 25 mM | 0.1281 mL | 0.6403 mL | 1.2805 mL | 3.2013 mL | |
| 30 mM | 0.1067 mL | 0.5336 mL | 1.0671 mL | 2.6678 mL | |
| 40 mM | 0.0800 mL | 0.4002 mL | 0.8003 mL | 2.0008 mL | |
| 50 mM | 0.0640 mL | 0.3201 mL | 0.6403 mL | 1.6007 mL | |
| 60 mM | 0.0534 mL | 0.2668 mL | 0.5336 mL | 1.3339 mL | |
| 80 mM | 0.0400 mL | 0.2001 mL | 0.4002 mL | 1.0004 mL | |
| 100 mM | 0.0320 mL | 0.1601 mL | 0.3201 mL | 0.8003 mL |
SPDP Related Classifications
HY-100216 Related Classifications
Powered by Bioz